Dapagliflozin in Patients With CKD With Fabry Disease
this preliminary evidence shows that dapagliflozin was associated with reduction in albuminuria, proteinuria, and eGFR decline in patients with FD and albuminuric CKD receiving ERT or migalastat and RAS-i over 12 months.
Authors
- Livia Lenzini
- Yuri Battaglia (ORCID: https://orcid.org/0000-0003-3947-1814)
- Federica Baciga
- Annalisa Sechi (ORCID: https://orcid.org/0000-0003-1708-7563)
- Giorgia Gugelmo (ORCID: https://orcid.org/0000-0002-3557-8078)
- Nicola Vitturi (ORCID: https://orcid.org/0000-0002-5147-4367)
- Pasquale B. Esposito (ORCID: https://orcid.org/0000-0002-0834-5586)
- Loris Martinetti
- Francesca Katiana Martino (ORCID: https://orcid.org/0000-0002-2402-9276)
- Francesca Viazzi (ORCID: https://orcid.org/0000-0003-4219-7043)
- Luca Zanoli (ORCID: https://orcid.org/0000-0003-1678-3778)
- Gianni Carraro (ORCID: https://orcid.org/0000-0003-0824-7692)
- Federica Caccia
- Domenico Girelli
- Gian Paolo Fadini
- Federico Nalesso
- Eleonora Riccio
- Lucia Federica Stefanelli
- Sara Torresani
- Antonio Pisani
- Giacomo Marchi
- Cristina Chimenti
Institutions
- University of Verona (IT)
- University of Udine (IT)
- University of Padua (IT)
- University of Catania (IT)
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Casa di Cura Villa Garda (IT)
- Policlinico Universitario di Catania (IT)
- Surgical Specialties (United States) (US)
- Ospedale Policlinico San Martino (IT)
- University of Genoa (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1016/j.ekir.2025.103742
- Primary Topic
- Lysosomal Storage Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00